Merck & Co., Inc. (ETR:6MK)

Market Cap	216.62B
Revenue (ttm)	61.98B
Net Income (ttm)	16.53B
Shares Out	n/a
EPS (ttm)	6.51
PE Ratio	13.10
Forward PE	n/a
Dividend	2.89 (3.40%)
Ex-Dividend Date	Mar 17, 2025

Volume	6,339
Average Volume	10,922
Open	83.70
Previous Close	83.00
Day's Range	83.50 - 85.00
52-Week Range	77.40 - 125.60
Beta	0.40
RSI	44.52
Earnings Date	Feb 4, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 72,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 6MK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD